These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 23753231)

  • 41. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia.
    Papazian L; Fraisse A; Garbe L; Zandotti C; Thomas P; Saux P; Pierrin G; Gouin F
    Anesthesiology; 1996 Feb; 84(2):280-7. PubMed ID: 8602657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
    Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
    Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current and future options for cytomegalovirus reactivation in hematopoietic cell transplantation patients.
    Maertens J; Lyon S
    Future Microbiol; 2017 Aug; 12():839-842. PubMed ID: 28745073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulmonary involvement during cytomegalovirus infection in immunosuppressed patients.
    de Maar EF; Verschuuren EA; Harmsen MC; The TH; van Son WJ
    Transpl Infect Dis; 2003 Sep; 5(3):112-20. PubMed ID: 14617298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.
    Gratama JW; van Esser JW; Lamers CH; Tournay C; Löwenberg B; Bolhuis RL; Cornelissen JJ
    Blood; 2001 Sep; 98(5):1358-64. PubMed ID: 11520783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytomegalovirus (CMV) DNA quantification in bronchoalveolar lavage fluid of immunocompromised patients with CMV pneumonia.
    Beam E; Germer JJ; Lahr B; Yao JDC; Limper AH; Binnicker MJ; Razonable RR
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29112278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
    Boeckh M; Nichols WG; Papanicolaou G; Rubin R; Wingard JR; Zaia J
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):543-58. PubMed ID: 14506657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.
    Slavin MA; Bindra RR; Gleaves CA; Pettinger MB; Bowden RA
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1360-3. PubMed ID: 8392311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival after cytomegalovirus pneumonia in two children receiving autologous peripheral blood progenitor cell transplantation (PBPCT).
    Castagnola E; Dallorso S; Rabagliati M; Sacco O; Kotitsa Z; Dini G
    Bone Marrow Transplant; 1998 Mar; 21(5):529-31. PubMed ID: 9535048
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation.
    Cui J; Zhao K; Sun Y; Wen R; Zhang X; Li X; Long B
    Front Immunol; 2022; 13():971156. PubMed ID: 36211358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients.
    Pollack M; Heugel J; Xie H; Leisenring W; Storek J; Young JA; Kukreja M; Gress R; Tomblyn M; Boeckh M
    Biol Blood Marrow Transplant; 2011 May; 17(5):664-73. PubMed ID: 20699126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand?
    Forman SJ; Zaia JA
    Blood; 1994 May; 83(9):2392-8. PubMed ID: 8167329
    [No Abstract]   [Full Text] [Related]  

  • 55. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
    Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
    N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG).
    Watson FS; O'Connell JB; Amber IJ; Renlund DG; Classen D; Johnston JM; Smith CB; Bristow MR
    J Heart Transplant; 1988; 7(2):102-5. PubMed ID: 2835468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation.
    Meesing A; Razonable RR
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):773-788. PubMed ID: 30009675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
    El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
    J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients.
    Royston L; Royston E; Masouridi-Levrat S; Chalandon Y; Van Delden C; Neofytos D
    Immun Inflamm Dis; 2021 Sep; 9(3):771-776. PubMed ID: 33949798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.